Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance

Clinical Cancer Research

Volumn 17, Issue 12, 2011, Pages 4155-4166

  Ponz Sarvisé, Mariano ^a,b   Nguewa, Paul A ^b   Pajares, María J ^b   Agorreta, Jackeline ^b   Lozano, María D ^a   Redrado, Miriam ^b   Pio, Ruben ^b   Behrens, Carmen ^c   Wistuba, Ignacio I ^c   García Franco, Carlos E ^a   García Foncillas, Jesús ^a,b   Montuenga, Luis M ^b   Calvo, Alfonso ^b   Gil Bazo, Ignacio ^a,b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INHIBITOR OF DIFFERENTIATION 1; MESSENGER RNA;

ADJUVANT THERAPY; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARCINOMA CELL; COHORT ANALYSIS; COMPUTER MODEL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; TISSUE LEVEL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; NEOPLASM STAGING; PROGNOSIS; RADIATION TOLERANCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TREATMENT OUTCOME;

EID: 79959246435     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3381     Document Type: Article

References (34)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-81.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009;59:225-49.
3. Win T, Sharples L, Groves AM, Ritchie AJ, Wells FC, Laroche CM. Predicting survival in potentially curable lung cancer patients. Lung 2008;186:97-102.
4. Feigenberg SJ, Hanlon AL, Langer C, Goldberg M, Nicolaou N, Millenson M, et al. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer. J Thorac Oncol 2007;2:287-92. (Pubitemid 47181710)
5. Albain KS, Swann RS, Rusch VW, Turrisi AT III, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-86.
6. Wang T, Nelson RA, Bogardus A, Grannis FW Jr. Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer 2010;116:1518-25.
7. Coate LE, John T, Tsao MS, Shepherd FA. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 2009;10:1001-10.
8. Ferte C, Andre F, Soria JC. Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol 2010;7:367-80.
9. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 1990;61:49-59.
10. Perk J, Iavarone A, Benezra R. Id family of helix-loop-helix proteins in cancer. Nat Rev Cancer 2005;5:603-14. (Pubitemid 41081386)
11. Yu X, Xu X, Han B, Zhou R. Inhibitor of DNA binding-1 overexpression in prostate cancer: relevance to tumor differentiation. Pathol Oncol Res 2009;15:91-6.
12. Ouyang XS, Wang X, Ling MT, Wong HL, Tsao SW, Wong YC. Id-1 stimulates serum independent prostate cancer cell proliferation through inactivation of p16(INK4a)/pRB pathway. Carcinogenesis 2002;23:721-5. (Pubitemid 34567509)
13. de Candia P, Solit DB, Giri D, Brogi E, Siegel PM, Olshen AB, et al. Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proc Natl Acad Sci U S A 2003;100:12337-42. (Pubitemid 37271561)
14. Li H, Gerald WL, Benezra R. Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade. Cancer Res 2004;64:6137-43. (Pubitemid 39129414)
15. Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O'Reilly R, et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 1999;401:670-7.
16. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008;319:195-8.
17. Gupta GP, Perk J, Acharyya S, de Candia P, Mittal V, Todorova- Manova K, et al. ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci U S A 2007;104:19506-11.
18. Perk J, Gil-Bazo I, Chin Y, de Candia P, Chen JJ, Zhao Y, et al. Reassessment of id1 protein expression in human mammary, prostate, and bladder cancers using a monospecific rabbit monoclonal anti-id1 antibody. Cancer Res 2006;66:10870-7. (Pubitemid 44876984)
19. Gil-Bazo I, Ponz-Sarvise M, Rosell D, Garcia-Foncillas J, Redrado M, Nguewa PA, et al. Use of inhibitor of differentiation-1 (Id1) expression (exp) to discriminate good prognosis (GP) from poor prognosis (PP) prostate cancer (PCa). J Clin Oncol [Genitourinary Cancers Symposium]. 2009. General Poster Session A: Prostate Cancer. Abstract No: 12.
20. Rothschild SI, Kappeler A, Ratschiller D, Betticher DC, Tschan MP, Gugger M, et al. The stem cell gene "inhibitor of differentiation 1" (ID1) is frequently expressed in non-small cell lung cancer. Lung Cancer 2010;71:306-11.
21. Kamalian L, Gosney JR, Forootan SS, Foster CS, Bao ZZ, Beesley C, et al. Increased expression of Id family proteins in small cell lung cancer and its prognostic significance. Clin Cancer Res 2008;14:2318-25. (Pubitemid 351551063)
22. Bhattacharya R, Kowalski J, Larson AR, Brock M, Alani RM. Id1 promotes tumor cell migration in nonsmall cell lung cancers. J Oncol 2010;2010, ID:856105.
23. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7. (Pubitemid 43128862)
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
25. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001;18:1059-68.
26. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4. (Pubitemid 41258223)
27. Irigoyen M, Pajares MJ, Agorreta J, Ponz-Sarvisé M, Salvo E, Lozano MD, et al. TGFBI expression is associated with a better response to chemotherapy in NSCLC. Mol Cancer 2010;9:130.
28. Masuda N, Fukuoka M, Takada M, Kudoh S, Kusunoki Y. Establishment and characterization of 20 human non-small cell lung cancer cell lines in a serum-free defined medium (ACL-4). Chest 1991;100:429-38.
29. Han S, Gou C, Hong L, Liu J, Zheyi Han, Liu C, et al. Expression and significances of Id1 helix-loop-helix protein overexpression in gastric cancer. Cancer Lett 2004;216:63-71. (Pubitemid 39410497)
30. Maw MK, Fujimoto J, Tamaya T. Overexpression of inhibitor of DNA-binding (ID)-1 protein related to angiogenesis in tumor advancement of ovarian cancers. BMC Cancer 2009;9:430.
31. Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC. The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 2010;28:5311-20.
32. Gautschi O, Tepper CG, Purnell PR, Izumiya Y, Evans CP, Green TP, et al. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res 2008;68:2250-8. (Pubitemid 351521798)
33. Caldon CE, Swarbrick A, Lee CS, Sutherland RL, Musgrove EA. The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini. Cancer Res 2008;68:3026-36. (Pubitemid 351556304)
34. Mern DS, Hasskarl J, Burwinkel B. Inhibition of Id proteins by a peptide aptamer induces cell-cycle arrest and apoptosis in ovarian cancer cells. Br J Cancer 2010;103:1237-44.